Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes
C Feng, W Chu, P Lin, H Xu, X Chen - Medicine, 2024 - journals.lww.com
This study aimed to elucidate 1-year outcomes following switching to the aflibercept (3 mg)
therapy for treatment-resistant wet age-related macular degeneration (wAMD). In this …
therapy for treatment-resistant wet age-related macular degeneration (wAMD). In this …
Switching between aflibercept and ranibizumab in the treatment of refractory exudative age-related macular degeneration
M Wichrowska, J Kocięcki… - OphthaTherapy. Therapies …, 2021 - journalsmededu.pl
Introduction: Aflibercept and ranibizumab have become the most used drugs in the treatment
of wet age-related macular degeneration. Some patients; however, do not respond to …
of wet age-related macular degeneration. Some patients; however, do not respond to …